Sector ratings Celltrion, Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 23/01/2026			5-day change	1st Jan Change
212,000.00 ^KRW	+1.92%		+1.44%	+17.13%

01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
CELLTRION, INC.	31.07B		A
LONZA GROUP AG	49.33B		AAA
SEAGEN INC.	43.15B	-	-	-	-	-	-	-
IQVIA HOLDINGS INC.	40.71B		AAA
BEONE MEDICINES AG	37.49B		-
REVOLUTION MEDICINES, INC.	22.97B	-	B	-		-
IMMUNOMEDICS, INC.	20.32B	-	-	-	-	-	-	-
MEDPACE HOLDINGS, INC.	17.08B		BBB
PPD, INC.	16.61B	-	-	-	-	-	-	-
EUROFINS SCIENTIFIC SE	14.81B		AA
ICON PUBLIC LIMITED COMPANY	14.26B		AA
ASCENDIS PHARMA A/S	14.03B	-	-	-		-
IONIS PHARMACEUTICALS, INC.	13.25B	-	A	-		-
TEMPUS AI, INC.	12.16B	-	A	-		-
QIAGEN N.V.	11.18B		AAA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	11.03B		A
BIO-TECHNE CORPORATION	10.85B		A
PRA HEALTH SCIENCES, INC.	10.96B	-	-	-	-	-	-	-
REGENCELL BIOSCIENCE HOLDINGS LIMITED	15.22B	-	-	-	-	-	-	-
PROMETHEUS BIOSCIENCES, INC.	9.56B	-	-	-	-	-	-	-
Average	20.8B		AA
Weighted average by Cap.			AA